Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies Read More »
Janet Rathod, who joins the system from Citigroup, will succeed long-time chief information security officer Darren Lacey.
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
Obesity Pill Races Heats Up as Novo, Roche and Terns Share Data Read More »
Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.
Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report Read More »
About half of employers said they would make cost-cutting changes to their plans next year, like increasing deductibles or other cost-sharing provisions, according to a report from consultancy Mercer.
Health benefit costs to rise 5.8% per employee in 2025: survey Read More »
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths Read More »
The newly approved filling line will be able to provide both 50-mg and 100-mg doses of the respiratory syncytial virus antibody Beyfortus to help meet demand ahead of the 2024/2025 RSV season.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application Read More »
In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis.
GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study Read More »
Qué es necesario para invertir en Bitcoin Comprar Bitcoin, a diferencia de otro tipo de operaciones de inversión, tiene unas exigencias específicas. Esto nos lo podemos encontrar en las criptomonedas en general, pero hacemos hincapié en esta porque, ade …
